ADAM10在非小细胞肺癌（NSCLC）的诊断、预后和转移中起着关键作用。

ADAM10 is a key player in the diagnosis, prognosis and metastasis of non-small cell lung cancer (NSCLC).

作者信息

Zhang Wenqian, Yang Liyao, Li Mufan, Zhang Lianmei, Cheng Jingliang, El-Far Ali H, Xu Youhua, Fu Junjiang

机构信息

Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macao 999078, China.

Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, Sichuan Province, China.

出版信息

J Cancer. 2025 Feb 11;16(5):1736-1746. doi: 10.7150/jca.107236. eCollection 2025.

DOI:10.7150/jca.107236

PMID:39991567

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11843235/

Abstract

A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) plays critical roles in various cancer-associated biological events, such as cell multiplication, migration, and metastasis. This study employs both the TCGA database and patient samples to demonstrate that ADAM10 is highly expressed in non-small cell lung cancer (NSCLC) compared with normal tissue at different stages. Increased ADAM10 expression is positively correlated with decreased overall and recurrence-free survival. On the functional front, overexpression of ADAM10 promotes lung cancer cell progression, migration, and invasion, whereas downregulation of ADAM10 inhibits these processes. Mechanically, ADAM10 modulates the expression of Notch1, MMP9 and EMT markers such as Vimentin, N-cadherin, and E-cadherin. Overall, our findings suggest that ADAM10 may be a promising therapeutic and prognostic marker for NSCLC, emphasizing the importance of regulating its expression.

摘要

含解整合素金属蛋白酶结构域蛋白10（ADAM10）在各种癌症相关的生物学事件中发挥着关键作用，如细胞增殖、迁移和转移。本研究利用TCGA数据库和患者样本证明，与不同阶段的正常组织相比，ADAM10在非小细胞肺癌（NSCLC）中高表达。ADAM10表达增加与总生存期和无复发生存期降低呈正相关。在功能方面，ADAM10的过表达促进肺癌细胞的进展、迁移和侵袭，而ADAM10的下调则抑制这些过程。在机制上，ADAM10调节Notch1、MMP9和EMT标志物（如波形蛋白、N-钙黏蛋白和E-钙黏蛋白）的表达。总体而言，我们的研究结果表明，ADAM10可能是NSCLC一个有前景的治疗和预后标志物，强调了调节其表达的重要性。